Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.

Abstract

PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.

Publication types

  • Clinical Trial

MeSH terms

  • B7-H1 Antigen / metabolism*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Humans
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / drug therapy
  • Nivolumab / pharmacokinetics
  • Positron-Emission Tomography*
  • Programmed Cell Death 1 Receptor / metabolism*
  • Radiopharmaceuticals / pharmacokinetics
  • Tissue Distribution
  • Treatment Outcome
  • Whole Body Imaging*

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Radiopharmaceuticals
  • Nivolumab